[Effects of several catecholamine-related drugs on aggressive behavior, brain noradrenaline content and tyramine uptake by isolated mice]. 1977

M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi

Such effects were studied in male albino mice maintained under isolation circumstances for 7 weeks in order to induce aggressiveness. L-DOPA (25 mg/kg) was given concomitantly with DDC (75 mg/kg) or reserpine (0.1 mg/kg), or each was administered signly and intraperitoneally to subjects twice weekly. Two peaks on the aggressive degree were observed at the 3rd-4th and 6th weeks, respectively. At the first peak, mice treated with L-DOPA and/or reserpine demonstrated aggressive behavior to a higher degree than control mice but at the second peak, to a lower degree. Mice treated with L-DOPA and DDC showed the highest degree at the second peak. Tyramine uptake in the brain measured at the 6th week was enhanced in mice treated with combinations of L-DOPA with reserpine or DDC. Noradrenaline content in the brain was lowered in mice treated with L-DOPA and/or reserpine, in comparison with each control value; It is thus concluded that catecholamine-related drugs influence the degree of enhancement of aggressiveness in modes which vary depending on the form of action of each drug.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D012110 Reserpine An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. Raunervil,Raupasil,Rausedil,Rausedyl,Serpasil,Serpivite,V-Serp,V Serp
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D004050 Ditiocarb A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM. Diethyldithiocarbamate,Diethylcarbamodithioic Acid,Diethyldithiocarbamic Acid,Dithiocarb,Ditiocarb Sodium,Ditiocarb, Ammonium Salt,Ditiocarb, Bismuth Salt,Ditiocarb, Lead Salt,Ditiocarb, Potassium Salt,Ditiocarb, Sodium Salt,Ditiocarb, Sodium Salt, Trihydrate,Ditiocarb, Tin(4+) Salt,Ditiocarb, Zinc Salt,Imuthiol,Sodium Diethyldithiocarbamate,Thiocarb,Zinc Diethyldithiocarbamate,Ammonium Salt Ditiocarb,Bismuth Salt Ditiocarb,Diethyldithiocarbamate, Sodium,Diethyldithiocarbamate, Zinc,Lead Salt Ditiocarb,Potassium Salt Ditiocarb,Sodium Salt Ditiocarb,Sodium, Ditiocarb,Zinc Salt Ditiocarb
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004336 Drug Antagonism Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy. Antagonism, Drug,Antagonisms, Drug,Drug Antagonisms

Related Publications

M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
November 1968, British journal of pharmacology,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
January 1979, Acta physiologica Polonica,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
January 1983, Neurochemistry international,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
January 1981, General pharmacology,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
June 1965, Experientia,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
May 1983, Pharmacology, biochemistry, and behavior,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
November 1965, Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
May 1969, European journal of pharmacology,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
August 1991, Biulleten' eksperimental'noi biologii i meditsiny,
M Kobayashi, and K Kawamura, and Y Gotoh, and H Sano, and K Hiraishi
October 1982, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!